大肠癌单克隆抗体治疗新进展  

Progression of monocolonal antibodies for colorectal cancer in 2008

作　　者：李进[1] 曹君[1] 

机构地区：[1]上海复旦大学附属肿瘤医院内科200032

出　　处：《临床肿瘤学杂志》2009年第1期1-5,共5页Chinese Clinical Oncology

摘　　要：表皮生长因子受体(EGFR)和血管内皮生长因子(VEGF)的过表达均与大肠癌肿瘤细胞生长有密切联系,如果阻断了EGFR或VEGF的活性,就可以阻断肿瘤细胞生长的重要过程,使得肿瘤细胞功能大大受损,从而起到了抗肿瘤的作用。作为EGFR和VEGF单克隆抗体,西妥昔单抗、贝伐单抗联合化疗治疗晚期恶性肿瘤,特别是大肠癌已经得到广泛应用,明显延长了患者的生存期,并成为晚期大肠癌治疗的一项重要飞跃。本文就2008年度有关抗EGFR单抗及贝伐单抗在大肠癌治疗中的最新研究进展做一综述。As we all know, overexpression of both epidermal growth factor receptor （EGFR） and vascular endothelial growth factor （EGFR） were critical in colorectal carcinogenesis. Tumor cell growth would be greatly blocked when EGFR or VEGF was obstructed. As a result, the EGFR monocolonal antibody cetuximab and VEGF monocolonal antibody bevacizumab came into being widely using for malignancies especially in mCRC. The combination of chemotherapy with cetuximab or bevacizumab have become standard regimens in advanced colorectal cancer and make a striking step to prolong the survival time in the past few years. Updates on EGFR and VEGF monocolonal antibodies in the treatment of colorectal cancer in year 2008 were reviewed in this article.

关 键 词：大肠癌 西妥昔单抗 贝伐单抗 帕尼单抗 K-RAS突变 

分 类 号：R730.54[医药卫生—肿瘤] R735.3[医药卫生—临床医学]